1-1 of 1
John Gibson, PhD
Close
Sort by
Journal Articles

Development of Retargeted CD38-Specific NK-92 Cell Line for Potential Anti-Myeloma Immunotherapy.

Shihong Yang, MMed, Xin An, PhD, Ross D. Brown, PhD, Joy Ho, PhD, John Gibson, PhD, Douglas E. Joshua, PhD, Winfried Wels, PhD, Daniel M. Sze, PhD
Journal: Blood
Blood (2005) 106 (11): 5104.
https://doi.org/10.1182/blood.V106.11.5104.5104
Published: 2005